Skip to content

The Pilot Study of High-throughput Sequencing in Neonatal Birth Defects

The Pre-clinical Study of Genomic Sequencing for Birth Defects in Newborns

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03984266
Enrollment
3423
Registered
2019-06-12
Start date
2019-10-01
Completion date
2021-12-31
Last updated
2022-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Birth Defect, Congenital Malformation, Genetic Diseases, Multiple Malformation, Newborn; Fit

Brief summary

In China, birth defects can reach as high as 5.6%, about 900,000 new cases of birth defects are added each year, making it the second cause of death for infants, with a total death rate of 19.1%. At present, China implements the three-level prevention and control system for birth defects, which is performed before marriage, before birth, and during the neonatal period. Newborn screening is the last line of defense against birth defects. Early screening diagnosis and timely intervention are extremely important, especially for diseases which can be preventive and treatable. This study aims to evaluate the clinical application of high-throughput targeting sequencing in newborns, and investigate whether this new technology can significantly shorten the time of examination, improve the diagnosis rate, guide the intervention treatments and promote prognosis for these disease.

Interventions

DIAGNOSTIC_TESTNGS panel

A next-generation-sequencing panel, which contains a group of genes that specifically cause disease, for mutational analysis in newborns.

Sponsors

Northwest Women's and Children's Hospital, Xi'an, Shaanxi
CollaboratorOTHER
Maternal and Child Health Hospital of Hubei Province
CollaboratorOTHER
The First Hospital of Jilin University
CollaboratorOTHER
Xuzhou Maternity and Child Health Care Hospital
CollaboratorOTHER
Children's Hospital of Chongqing Medical University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
1 Minutes to 28 Days
Healthy volunteers
No

Inclusion criteria

1. Neonates in one of the study hospitals 2. Abnormal laboratory testing or abnormal response to standard therapy suggestive of a genetic disease

Exclusion criteria

1. Any infant whose genome has been shown to have large chromosomal aberration (Trisomy 13, 18, 21 or other) 2. Any infant in which clinical considerations preclude drawing 1.0 ml of peripheral blood 3. Parents refuse consent

Design outcomes

Primary

MeasureTime frameDescription
MortalityAt corrected age of 18 monthsIncidence of death
Disability RateAt corrected age of 18 monthsIncidence of disability. Disability defined as a physical or mental handicap, especially one that prevents a person from living a full, normal life or from holding a gainful job.
Allele FrequencyIn 120 days after receipt of all the patients' sequencing dataAllele frequency, or gene frequency, is the relative frequency of an allele (variant of a gene) at a particular locus in the population the investigators studied, expressed as a percentage.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026